Anthropic unveiled Claude Science at an event for pharma and biotech leaders, positioning it as an autonomous research tool analogous to Claude Code for software engineering.
Anthropic has announced Claude Science, a new product designed to support scientific research, the company revealed at an event attended by pharmaceutical executives, biotech founders, and researchers. [1]
The product is modeled on Claude Code, Anthropic’s software-engineering tool, and is built to autonomously carry out meaningful work from concise, high-level instructions. [1] It includes tools specifically aimed at computational biology and drug development. [1]
Anthropic said it will also deploy Claude Science in its own internal research into drugs for rare and neglected diseases, signaling that the company intends to use the product beyond commercial licensing. [1]
The launch comes as the broader AI-for-drug-discovery space is attracting significant attention. On average, developing a new drug takes more than ten years and costs billions of dollars, and a growing number of startups are betting that machine-learning models can shorten that timeline by predicting how potential drug compounds might behave in the body and eliminating dead-end candidates before lab work begins. [1]
Separately, the United States lifted export restrictions on Anthropic’s Mythos and Fable models, with Anthropic saying it would begin restoring access on July 1, 2026, following lengthy talks with the company. [1] The controls had originally been imposed over security concerns, and reports indicate the crackdown had already created openings for Chinese AI rivals in affected markets. [1]
Sources
This article was drafted with AI from the cited sources and checked against them before publication. Spot an error? Let us know.
